VGL101 for Leukoencephalopathy
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing iluzanebart, a medication given through infusions, in adults with a specific genetic mutation causing ALSP, a rare brain disease. The goal is to see if the medication is safe and can slow down the disease by looking at brain scans and other health markers. Participants will receive the treatment regularly for a year, with an option to continue for additional years.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Are You a Good Fit for This Trial?
This trial is for adults with a specific brain condition called ALSP, confirmed by MRI and genetic testing showing a CSF1R gene mutation. Participants must have someone to report on their health status. Those with other neurological conditions that could confuse study results or pose significant risks are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Core Study
Participants receive infusions of iluzanebart approximately every 4 weeks for 1 year to assess safety, tolerability, and effects on imaging and biomarkers
Long-Term Extension
Participants who complete the Core Study may opt to continue treatment for up to an additional 2 years
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- VGL101
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vigil Neuroscience, Inc.
Lead Sponsor